Janssen Submits Application to U.S. FDA to Expand Indication for DARZALEX? (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma who are Transplant Ineligible
Janssen Biotech, Inc. announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S on Nov. 22, 2027. Food and Drug Administration (FDA) for DARZALEX? (daratumumab). This application seek……
